NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Finally, those last 31 patients would have entered the trial between August 2015 and November 2015. The date that the blended data was determined was in March 2017, 16 to 20 months later. So I think that would mean that all patients alive on the chart at 16 to 18 months in March 2017 would have been from that group of 31. I think that would be at about censored patient 10 on the combined chart to censored patient 30, or about 21 patients (you don't subtract - but start with 10 and count to 30). On the methylated chart, that's patient #4 to patient #15, or 12 patients. On the unmethylated chart, that's patient #6 to patient #14 or 9 patients. We don't know how the remaining 10 patients were broken down as to their methylation status. But still... that's 67% of the 31 still alive between 16 to 20 months - it's really 18 months as there were none alive at 16 months. If those 31 followed the entire trial in terms of how many were methylated and unmethylated (45% and 55%), then there would have been about 14 methylated, and 17 unmethylated.

At least that's how I see it. Maybe I'm missing something.

Sentiment,

The OS curve is from surgery and not from enrollment!
The last 31 patients had their surgery between May 15, 2015 and August 20, 2015.
These are the censors between 18 months and 10 days and 21 and 1/2 months on the OS curve. Censor 12 to censor 37 = 26 patients.
26 patients still alive.

31 randomized 2:1? I doubt it. (IMO)

Sentiment curve: https://investorshub.advfn.com/uimage/uploads/2018/10/22/gddzjCombined_charts_no_notes_revised_-lykiri.jpg